Reviva Company Equity Multiplier from 2010 to 2025

RVPHW Stock  USD 0.27  0.11  68.75%   
Reviva Pharmaceuticals Company Equity Multiplier yearly trend continues to be fairly stable with very little volatility. Company Equity Multiplier is likely to outpace its year average in 2025. During the period from 2010 to 2025, Reviva Pharmaceuticals Company Equity Multiplier regression line of quarterly data had mean square error of  0.88 and geometric mean of  0.01. View All Fundamentals
 
Company Equity Multiplier  
First Reported
2010-12-31
Previous Quarter
3.73
Current Value
3.92
Quarterly Volatility
1.5533384
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Reviva Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Reviva Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 10 K, Net Interest Income of 602.5 K or Interest Income of 602.5 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 20.25. Reviva financial statements analysis is a perfect complement when working with Reviva Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Reviva Pharmaceuticals Correlation against competitors.

Latest Reviva Pharmaceuticals' Company Equity Multiplier Growth Pattern

Below is the plot of the Company Equity Multiplier of Reviva Pharmaceuticals Holdings over the last few years. It is Reviva Pharmaceuticals' Company Equity Multiplier historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Reviva Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Company Equity Multiplier10 Years Trend
Slightly volatile
   Company Equity Multiplier   
       Timeline  

Reviva Company Equity Multiplier Regression Statistics

Arithmetic Mean0.98
Geometric Mean0.01
Coefficient Of Variation159.31
Mean Deviation1.22
Median(0.0004)
Standard Deviation1.55
Sample Variance2.41
Range4.1447
R-Value0.81
Mean Square Error0.88
R-Squared0.66
Significance0.0001
Slope0.27
Total Sum of Squares36.19

Reviva Company Equity Multiplier History

2025 3.92
2024 3.73
2023 4.14
2022 1.54
2021 1.09
2020 1.18

About Reviva Pharmaceuticals Financial Statements

Reviva Pharmaceuticals investors use historical fundamental indicators, such as Reviva Pharmaceuticals' Company Equity Multiplier, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Reviva Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Company Equity Multiplier 3.73  3.92 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Reviva Stock Analysis

When running Reviva Pharmaceuticals' price analysis, check to measure Reviva Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Reviva Pharmaceuticals is operating at the current time. Most of Reviva Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Reviva Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Reviva Pharmaceuticals' price. Additionally, you may evaluate how the addition of Reviva Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.